Skip to content
Peptide research

LL-37

Also known as Cathelicidin
Category
Immune & Defense
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A natural cathelicidin antimicrobial peptide, marketed for infection, biofilms, and wound healing. Its antimicrobial and wound-healing effects are moderately supported and rest largely on lab and animal work, with thin human data and speculative anticancer claims. The main safety gap is cell toxicity at high doses (including red blood cell rupture) plus a self-DNA autoimmune link. Not an approved US drug, and unregulated products sold online are of uncertain purity.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Broad-spectrum antimicrobial activity

    Medium

    Disrupts membranes of many bacteria, fungi, and enveloped viruses in laboratory tests.

  • Anti-biofilm activity

    Low

    Prevents and breaks up bacterial biofilms in lab studies, not yet tested in people.

  • Wound healing acceleration

    Medium

    A human trial found topical use sped venous leg ulcer healing versus placebo.

Evidence limits

Evidence Level
Moderate

A 34-person venous-ulcer trial reported improved healing predictors, and a 25-person diabetic-foot-ulcer trial found improved granulation. A larger 148-person venous-ulcer trial found no significant overall healing benefit; favorable subgroup findings were exploratory. Phase I melanoma trial (NCT02225366) completed. A small exploratory study evaluated oral LL-37 for COVID-19. Most evidence remains preclinical, and the clinical wound-healing evidence is mixed.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Autoimmune conditions (psoriasis, lupus)

    High

    LL-37 is elevated in psoriatic lesions and may exacerbate autoimmune skin conditions. Forms DNA complexes that activate autoimmune pathways.

  • Rosacea

    Moderate

    LL-37 is pathogenically elevated in rosacea. Exogenous administration may worsen the condition.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • At high concentrations LL-37 can damage human cells including red blood cells (hemolysis)

    Moderate
  • LL-37 is rapidly broken down by proteases, limiting half-life

    Moderate
  • LL-37 complexed with self-DNA can activate plasmacytoid dendritic cells (autoimmunity link)

    Moderate
  • Bacteria can develop resistance to LL-37 through membrane modifications

    Moderate
  • LL-37 antimicrobial activity diminished by serum, salt, and divalent cations

    High
  • The melanoma trial (NCT02225366) noted dermatologic toxicity at intratumoral injection sites

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.